Navigation Links
New old drug fights colon cancer
Date:10/13/2009

A new Tel Aviv University drug, based on an older generation antibiotic, may provide doctors with an effective and innovative method of treating colon cancer in both its incipient and full-blown stages ― and minimize the need for painful, uncomfortable colonoscopies and surgical polyp removal.

Dr. Rina Rosin-Arbesfeld of TAU's Sackler School of Medicine has shown in preclinical studies that a common antibiotic can suppress the growth of colon cancer polyps in mice. Her aim is to reformulate the drug for use as a preventative therapy ― or, in stronger doses, in combination with chemotherapy and radiation to fight existing cancers until they're gone. The current formulation reduced the size of the polyps in about 80% of the mice she studied, and on average the animals lived 30% longer than those who were not given the antibiotic.

"My experience shows that colon cancer is particularly aggressive," says Dr. Rosin-Arbesfeld. "Our new drug may be able to slow down polyp growth so that it never manifests to full-blown colon cancer." She is currently preparing the results of her recent study for an upcoming issue of the journal Gut.

Taking genes to the repair shop

The antibiotic acts in a genetic fashion. In diseases like cystic fibrosis (CF) and muscular dystrophy, antibiotics from the aminiglycoside family can repair damaged or mutated DNA. For her new study, Dr. Rosin-Arbesfeld looked at a closely-related but less toxic family of antibiotics from the Macrolide family that achieves the same therapeutic results.

Dr. Rosin-Arbesfeld focused on a gene associated with colorectal cancer, the APC gene, and noticed that the mutation types in colorectal cancer are similar to those in the CF gene. Noting that old generation antibiotics are effective in fighting CF, she studied its effects on colon cancer as well. She found that the drug partially repaired faulty genes in mice with colon cancer. Benefits from u
'/>"/>

Contact: George Hunka
ghunka@aftau.org
212-742-9070
American Friends of Tel Aviv University
Source:Eurekalert  

Page: 1 2

Related medicine news :

1. Bay Medical Fights Healthcare-Associated Infections by Improving Hand Hygiene 300%
2. Irish Joe McCreedy Defends Title, Fights for New One With Superhydration From AquaHydrate, First High Performance Sports Water
3. Biotransformed blueberry juice fights fat and diabetes
4. New Precision Radiation Treatment System Fights Cancer
5. Most Americans Continue to Support Moving Ahead With Health Care Reform Now Despite Town Hall Fights and Ad Campaigns
6. Indoor Tanning Association Fights Back Against Media Hype over Tanning Beds
7. New Drug Fights Anthrax Toxin
8. New Cancer Drug Fights Tumors in Those With BRCA Mutations
9. Researchers at Case Western Reserve discover a new way the body fights fungal infection
10. New Insights Show Ginseng Fights Inflammation
11. New Discovery Shows Ancient Herb Fights Inflammation
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New old drug fights colon cancer
(Date:1/22/2015)... Deer Path of Huntley -- a ... Happy Hour from 3 p.m. to 4 p.m. on Feb. 13. ... Huntley, Illinois, serves adults with physical disabilities between the ages of ... Day treats, games and sweetheart-themed karaoke. , For more information about ...
(Date:1/22/2015)... January 22, 2015 Woodloch Pines, an ... been selected by TripAdvisor as the number one best large ... best in the world for their annual Travelers’ Choice Awards. ... community . The website is home to millions of unbiased ...
(Date:1/22/2015)... (PRWEB) January 23, 2015 Angelweddingdress is a ... business invites its customers to follow it on Facebook, Twitter, ... a Valentine’s Day gift. Angelweddingdress draws a lottery every week. ... Sale to Feb. 28, 2015. Click Angelweddingdress homepage ...
(Date:1/22/2015)... 2015 A new white paper by ... person-centeredness in the long-term care environment as well as ... continuum. The paper, “The Power of Person-Centeredness in Long-Term ... practices of the patient, resident and family experience in ...
(Date:1/22/2015)... 22, 2015 Joan Lunden, award-winning American ... at the upcoming 32nd Annual Miami Breast Cancer ... Education Resource®, LLC (PER®) , shares that “a fast-growing, ... undetected if she had not followed up her clean ...
Breaking Medicine News(10 mins):Health News:Deer Path of Huntley Affordable Assisted Living to Host Valentine's Day Happy Hour 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 3Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6
... , , ... Democrat in Arcadia, LA recently reported that ... in treating cancers, introducing many new, breakthrough medicines . ... 861 new cancer medicines that are either in late-stage testing, ...
... , , MINNEAPOLIS , Jan. 29 ... it will continue to support efforts to save the General Assistance ... in payments for services, since the existing payments already do not ... to support broad-based tax increases that would support health care programs. ...
... , Statement by Jim Wordelman State Director for AARP Idaho ... of Congress figure out the next steps to take to tackle health ... by the day.  It,s time for Idaho ,s state and federal ... businesses, and retirees to deliver solutions as opposed to more roadblocks to ...
... , LOS ANGELES , Jan. 29 In a ... the nation,s organ donation and transplant community will vote for the best ... Seven Pounds , Return to Me , John Q ... Philadelphia Transplant Movie Night, a group of transplant recipients, living donors and ...
... Bill & Melinda Gates Foundation announced it would dedicate ... vaccine research, development and delivery throughout the developing world. ... pneumonia, diarrhea and malaria take the lives of 5 ... simply because life-saving vaccines don,t reach those who need ...
... Project A.L.S. (New York, NY) and the Robert Packard ... MD) announced that they will partner on, P2 ALS, ... Gehrig,s disease) research exponentially over the next three years. ... leaders in forging productive collaborations among research scientists, will ...
Cached Medicine News:Health News:Cancer Medicines Pipeline Offers Patients Great Hope 2Health News:Doctors Tell Lawmakers to Find a New GAMC Fix 2Health News:Idaho's Health Care Woes Need Solutions, Not More Roadblocks 2Health News:Idaho's Health Care Woes Need Solutions, Not More Roadblocks 3Health News:Nationwide Vote to Determine Best Organ Donation-Themed Movie 2Health News:Project A.L.S. and Packard Center take aim at ALS with $15 million program 2
(Date:1/23/2015)... , Jan. 23, 2015 Gem Pharmaceuticals announced ... have been enrolled into the Company,s Phase 2 clinical ... safety of Gem,s lead compound, GPX-150 (an investigational medication), ... or metastatic disease. Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO ...
(Date:1/22/2015)... UPI ), a medical device company that develops, ... dysfunctions, today reported financial results for the fiscal 2015 ... for the Company,s Urgent ®  PC Neuromodulation System grew ... as compared to $3.9 million in the third quarter ...
(Date:1/22/2015)... Jan. 22, 2015  Profil Institute for Clinical Research, Inc., ... obesity, announced today a new textbook,  Translational Research Methods ... Springer, a leading global scientific publisher. The ... techniques for use in early phase clinical studies of ...
Breaking Medicine Technology:Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 3Uroplasty Reports Record Revenue in Fiscal Third Quarter 4Uroplasty Reports Record Revenue in Fiscal Third Quarter 5Uroplasty Reports Record Revenue in Fiscal Third Quarter 6Uroplasty Reports Record Revenue in Fiscal Third Quarter 7Uroplasty Reports Record Revenue in Fiscal Third Quarter 8Uroplasty Reports Record Revenue in Fiscal Third Quarter 9Uroplasty Reports Record Revenue in Fiscal Third Quarter 10Uroplasty Reports Record Revenue in Fiscal Third Quarter 11Uroplasty Reports Record Revenue in Fiscal Third Quarter 12Uroplasty Reports Record Revenue in Fiscal Third Quarter 13Uroplasty Reports Record Revenue in Fiscal Third Quarter 14Uroplasty Reports Record Revenue in Fiscal Third Quarter 15Uroplasty Reports Record Revenue in Fiscal Third Quarter 16Uroplasty Reports Record Revenue in Fiscal Third Quarter 17Uroplasty Reports Record Revenue in Fiscal Third Quarter 18New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 2New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 3
... UCB today announced new ... (certolizumab pegol) was associated with a rapid and sustained ... of moderate to severe rheumatoid arthritis (RA) patients. The ... 2011 Annual Scientific Meeting in Chicago, November 5-9, are ...
... Amgen (NASDAQ: AMGN ) and Pfizer Inc. ... second and final period of the PRESERVE trial.  PRESERVE is ... arthritis (RA) who achieved Disease Activity Score (DAS) 28 low ... plus methotrexate (MTX) in Period one and were randomized to ...
Cached Medicine Technology:New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T 2New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T 3New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T 4New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T 5New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T 6New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T 7New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T 8New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T 9New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T 10New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T 11Treatment With Enbrel® (etanercept) Shows Significant and Sustained Clinical Benefits in Rheumatoid Arthritis (RA) Patients With Moderately Active Disease 2Treatment With Enbrel® (etanercept) Shows Significant and Sustained Clinical Benefits in Rheumatoid Arthritis (RA) Patients With Moderately Active Disease 3Treatment With Enbrel® (etanercept) Shows Significant and Sustained Clinical Benefits in Rheumatoid Arthritis (RA) Patients With Moderately Active Disease 4Treatment With Enbrel® (etanercept) Shows Significant and Sustained Clinical Benefits in Rheumatoid Arthritis (RA) Patients With Moderately Active Disease 5Treatment With Enbrel® (etanercept) Shows Significant and Sustained Clinical Benefits in Rheumatoid Arthritis (RA) Patients With Moderately Active Disease 6Treatment With Enbrel® (etanercept) Shows Significant and Sustained Clinical Benefits in Rheumatoid Arthritis (RA) Patients With Moderately Active Disease 7Treatment With Enbrel® (etanercept) Shows Significant and Sustained Clinical Benefits in Rheumatoid Arthritis (RA) Patients With Moderately Active Disease 8Treatment With Enbrel® (etanercept) Shows Significant and Sustained Clinical Benefits in Rheumatoid Arthritis (RA) Patients With Moderately Active Disease 9Treatment With Enbrel® (etanercept) Shows Significant and Sustained Clinical Benefits in Rheumatoid Arthritis (RA) Patients With Moderately Active Disease 10Treatment With Enbrel® (etanercept) Shows Significant and Sustained Clinical Benefits in Rheumatoid Arthritis (RA) Patients With Moderately Active Disease 11
...
Ascent Primary Knee System with cruciate retaining, posterior stabilized and constrained components...
Ascent Primary Knee System with cruciate retaining, posterior stabilized and constrained components...
... continues the "Consensus Concept" approach to design ... experience of a Scientific Advisory Board. The ... incorporates state-of-the-art features. Consensus Knee implants are ... stability and allow near normal kinematics. The ...
Medicine Products: